Topic
Hyperthermia
About: Hyperthermia is a research topic. Over the lifetime, 5851 publications have been published within this topic receiving 153538 citations. The topic is also known as: overheating & heat stroke.
Papers published on a yearly basis
1 / 2
Papers
TL;DR: For every particular temperature-dependent interaction exploited for clinical purposes, sophisticated control of temperature, spatially as well as temporally, in deep body regions will further improve the potential.
Abstract: Hyperthermia, the procedure of raising the temperature of tumour-loaded tissue to 40-43 degrees C, is applied as an adjunctive therapy with various established cancer treatments such as radiotherapy and chemotherapy. The potential to control power distributions in vivo has been significantly improved lately by the development of planning systems and other modelling tools. This increased understanding has led to the design of multiantenna applicators (including their transforming networks) and implementation of systems for monitoring of E-fields (eg, electro-optical sensors) and temperature (particularly, on-line magnetic resonance tomography). Several phase III trials comparing radiotherapy alone or with hyperthermia have shown a beneficial effect of hyperthermia (with existing standard equipment) in terms of local control (eg, recurrent breast cancer and malignant melanoma) and survival (eg, head and neck lymph-node metastases, glioblastoma, cervical carcinoma). Therefore, further development of existing technology and elucidation of molecular mechanisms are justified. In recent molecular and biological investigations there have been novel applications such as gene therapy or immunotherapy (vaccination) with temperature acting as an enhancer, to trigger or to switch mechanisms on and off. However, for every particular temperature-dependent interaction exploited for clinical purposes, sophisticated control of temperature, spatially as well as temporally, in deep body regions will further improve the potential.
2,087 citations
TL;DR: Hyperthermia can inhibit TGF-β1-induced EMT in HepG2 cells, suggesting that hyperthermia may alter the properties of metastatic potential in cancer cells and inhibit tumor metastasis.
Abstract: Background/aims EMT plays an essential role in tumor progression and metastasis Hyperthermia is a potent approach for cancers with low side effects However, the effect of hyperthermia on EMT of cancer cells is unknown Methodology Cells were treated with TGF-β1 and epidermal growth factor for 96 h and then exposed to hyperthermia at 43°C for 05 h Cell morphology was observed Expressions of E-cadherin and vimentin were determined by Western blot The protein and mRNA expressions of Snail were detected with Western blot and RT-PCR Cell migratory capacity was evaluated Results TGF-β1 induced EMT in HepG2 cells, which was evidenced by morphological, molecular and functional changes, including the formation of spindle shape and the loss of cell contact The expression of E-cadherin was decreased but the expression of vimentin increased; also, the migratory capability was increased by 21±019-fold as compared with untreated cells However, those effects were inhibited by the treatment of hyperthermia Furthermore, the protein and mRNA expressions of Snail induced by TGF-β1 were also significantly inhibited by hyperthermia treatment Conclusions Hyperthermia can inhibit TGF-β1-induced EMT in HepG2 cells, suggesting that hyperthermia may alter the properties of metastatic potential in cancer cells and inhibit tumor metastasis
1,847 citations
TL;DR: The direct cytotoxic effect of heat, heat-induced alterations of the tumor microenvironment, synergism of heat in conjunction with radiation and drugs, as well as, the presumed cellular effects of hyperthermia including the expression of heat-shock proteins (HSP), induction and regulation of apoptosis, signal transduction, and modulation of drug resistance byhyperthermia are discussed.
Abstract: In oncology, the term 'hyperthermia' refers to the treatment of malignant diseases by administering heat in various ways. Hyperthermia is usually applied as an adjunct to an already established treatment modality (especially radiotherapy and chemotherapy), where tumor temperatures in the range of 40-43 degrees C are aspired. In several clinical phase-III trials, an improvement of both local control and survival rates have been demonstrated by adding local/regional hyperthermia to radiotherapy in patients with locally advanced or recurrent superficial and pelvic tumors. In addition, interstitial hyperthermia, hyperthermic chemoperfusion, and whole-body hyperthermia (WBH) are under clinical investigation, and some positive comparative trials have already been completed. In parallel to clinical research, several aspects of heat action have been examined in numerous pre-clinical studies since the 1970s. However, an unequivocal identification of the mechanisms leading to favorable clinical results of hyperthermia have not yet been identified for various reasons. This manuscript deals with discussions concerning the direct cytotoxic effect of heat, heat-induced alterations of the tumor microenvironment, synergism of heat in conjunction with radiation and drugs, as well as, the presumed cellular effects of hyperthermia including the expression of heat-shock proteins (HSP), induction and regulation of apoptosis, signal transduction, and modulation of drug resistance by hyperthermia.
1,736 citations
TL;DR: The clinical results achieved to date have confirmed the expectations raised by results from experimental studies and justify using hyperthermia as part of standard treatment in tumour sites for which its efficacy has been proven and, furthermore, to initiate new studies with other tumours.
1,163 citations
TL;DR: The two principal rationales for applying hyperthermia in cancer therapy are that: the S phase, which is relatively radioresistant, is the most sensitive phase tohyperthermia, and can be selectively radiosensitized by combining hyperThermia with x-irradiation, and the cycling tumor cells in S phase could be killed by subjecting these cells toHyperthermia.
Abstract: The two principal rationales for applying hyperthermia in cancer therapy are that: (a) the S phase, which is relatively radioresistant, is the most sensitive phase to hyperthermia, and can be selectively radiosensitized by combining hyperthermia with x-irradiation; the cycling tumor cells in S phase which would normally survive an x-ray dose could thus be killed by subjecting these cells to hyperthermia; and (b) the relatively radioresistant hypoxic cells in the tumor may be selectively destroyed by combinations of hyperthermia and x-irradiation. Both of these rationales have been mentioned as reasons for using high LET irradiation in cancer therapy; therefore where such irradiation may be of use, hyperthermia may also be advantageous.
974 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2026 | 2 |
| 2025 | 214 |
| 2024 | 312 |
| 2023 | 423 |
| 2022 | 571 |
| 2021 | 158 |